Key facts
- This page summarizes Mark J. Alles's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Sep 2023, 16:47.
Mark J. Alles - 16 Sep 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)
- Reporting relationship
- Director
- Issuer ticker
- SYRS
- Reported as of
- 16 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Sep 2023, 16:47:30 UTC
- Prior SEC filing
- 02 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Todd Rosenthal, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark J. Alles filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 19 Sep 2023.
Change
- Previous filing in this sequence was filed on 02 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SYRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,666
- Change %
- +267%
- Price
- Shares after
- 3,666
- Date
- 16 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,666
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 5,334
- Date
- 16 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,666
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a restricted stock unit award.
Footnote F2
On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Footnote F3
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
Footnote F4
Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.